MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation

Ann Hematol. 2015 Jul;94(7):1081-92. doi: 10.1007/s00277-015-2369-0. Epub 2015 Apr 22.

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) is a well-established treatment for many malignant and non-malignant hematological disorders. As frequent complication in up to 50 % of all patients, graft-versus-host disease (GVHD) is still the main cause for morbidity and non-relapse mortality. Diagnosis of GVHD is usually done clinically, even though confirmation by pathology is often used to support the clinical findings. Effective treatment requires intensified immunosuppression as early as possible. Although several promising biomarkers have been proposed for an early diagnosis, no internationally recognized consensus has yet been established. Here, microRNAs (miRs) represent an interesting tool since miRs have been recently reported to be an important regulator of various cells, including immune cells such as T cells. Therefore, we could assume that miRs play a key role in the pathogenesis of acute GVHD, and their detection might be an interesting possibility in the early diagnosis and monitoring of acute GVHD. Recent studies additionally demonstrated the implication of miRs in the pathogenesis of acute GVHD. In this review, we aim to summarize the previous reports of miRs, focusing on the pathogenesis of acute GVHD and possible implications in diagnostic approaches.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / genetics
  • Graft vs Host Disease / metabolism*
  • Humans
  • MicroRNAs / biosynthesis*
  • MicroRNAs / genetics
  • Stem Cell Transplantation / adverse effects*
  • Stem Cell Transplantation / trends
  • Transplantation, Homologous / adverse effects
  • Transplantation, Homologous / trends

Substances

  • Biomarkers
  • MicroRNAs